A framework for athletic organizations to implement biomarker-based concussion management — covering baseline testing, incident response, threshold protocols, and liability reduction.
Concussion management in sport has long depended on symptom self-report and sideline cognitive testing. Both are necessary. Neither is sufficient. Athletes minimize symptoms to keep playing; cognitive tests are subject to learning effects and effort.
Biomarkers add an objective layer to that decision — one that does not depend on what an athlete is willing to disclose.
Symptom checklists rely on honesty. Sideline cognitive tests rely on effort. Imaging rarely shows anything in a mild concussion. Return-to-play decisions are made under time pressure with incomplete information.
The result is well documented: athletes returning to play while still injured, and a meaningful rate of second-impact exposure that compounds risk.
A biomarker-based protocol uses three measurement points: a pre-season baseline, an incident draw within hours of a suspected injury, and one or more follow-up draws during recovery.
Comparing an athlete to their own baseline is more informative than comparing them to a population norm. Small relative changes that would be invisible against a population average become clearly visible against an individual baseline.
Operationalize results with a three-tier protocol: Green (within baseline range — standard graduated return), Yellow (mild elevation — extended observation, repeat testing), Red (significant elevation — medical evaluation, no contact activity).
Thresholds are configured to the program, the athlete population, and the assay used. The structure is the same; the cut-points are local.
The NFL settlement is over $1.18 billion and counting. Concussion-related litigation has expanded to college, high school, and youth programs. The legal question increasingly turns on what an organization knew, when, and what protocols it had in place.
Documented use of objective testing strengthens the organization’s position on standard of care. The absence of objective testing, given current science, is becoming harder to defend.
Beyond single incidents, baseline drift across seasons can indicate cumulative sub-clinical exposure. NfL is particularly useful for that trajectory analysis — it turns “getting your bell rung” from anecdote into trend data.
Programs that monitor longitudinally can intervene before cumulative damage becomes symptomatic.
Three components: a relationship with an accredited lab, a medical team trained on biomarker interpretation, and a written protocol that defines when draws happen and what each result triggers.
NWP Healthcare provides program design, lab logistics, and clinical support for athletic organizations implementing biomarker-based concussion management.
References cited in this article and recommended materials for deeper study.
© 2026 New World Partners Healthcare. All rights reserved.
